R&D/ Views & Analysis/ Views and analysis Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4 mike.hammerton@pharmaphorum.com Biogen, GSK, Merck, Q4 2021, quarterly results 0 Comment While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning Share X Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4 https://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-pipeline-continues-to-provide-drama-as-investors-look-beyond-covid-in-q4/
